Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term

Becton Dickinson (BDX), a medical technology company, is identified as a potential growth stock despite holding a Zacks Rank #3 (Hold). The company exhibits strong growth metrics, including a Growth Style Score of B and a VGM Score of B, with a projected 9.1% year-over-year earnings growth for the current fiscal year. Analyst sentiment is positive, with nine analysts revising fiscal 2025 earnings estimates higher by $0.17 to $14.34 per share in the past 60 days, complemented by an average earnings surprise of +6.5%, suggesting BDX warrants consideration for growth-focused portfolios.

Analysis

Becton Dickinson (BDX) presents a nuanced investment case, characterized by a neutral Zacks #3 (Hold) rank that contrasts with strong underlying growth fundamentals. The medical technology company is projected to deliver 9.1% year-over-year earnings growth for the current fiscal year, supported by a 'B' grade in both its Growth and overall VGM Style Scores. More significantly, forward-looking sentiment appears to be improving, as evidenced by nine analysts revising fiscal 2025 earnings estimates higher over the last 60 days. This has lifted the Zacks Consensus Estimate for fiscal 2025 by $0.17 to $14.34 per share. This positive revision trend, coupled with a historical average earnings surprise of +6.5%, suggests that while the stock may lack immediate-term catalysts implied by its 'Hold' rating, its fundamental growth trajectory is strengthening.

Key Decisions for Investors

• Investors should consider looking past the neutral Zacks #3 'Hold' rating, as the positive underlying growth metrics and upward earnings revisions may signal future upside not yet reflected in the current rank.
• Given the positive shift in analyst sentiment for fiscal 2025, monitor for a potential upgrade of the primary Zacks Rank, which could serve as a key catalyst for the stock.
• For growth-oriented portfolios, BDX warrants consideration for a long-term position based on its forecasted 9.1% earnings growth and a consistent track record of beating earnings expectations by an average of 6.5%.